# LIST OF CONTENTS

<table>
<thead>
<tr>
<th>Chapter No.</th>
<th>Title</th>
<th>Page No.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Copyright Certificate</td>
<td>i</td>
</tr>
<tr>
<td></td>
<td>Declaration</td>
<td>ii</td>
</tr>
<tr>
<td></td>
<td>Certificate</td>
<td>iii</td>
</tr>
<tr>
<td></td>
<td>Acknowledgement</td>
<td>iv</td>
</tr>
<tr>
<td></td>
<td>List of Tables</td>
<td>vi</td>
</tr>
<tr>
<td></td>
<td>List of Figures</td>
<td>vii</td>
</tr>
<tr>
<td></td>
<td>List of Abbreviations</td>
<td>x</td>
</tr>
</tbody>
</table>

1 **Introduction** 1-22

1.1 Fixed dose combinations (FDCs) 1
1.2 Stability testing of pharmaceutical products 7
1.3 Impurities in pharmaceutical products 11
1.4 LC/MS method development 17
1.5 Method validation 18
1.6 UPLC-QTOF-MS 21

2 **Literature Review** 23-45

3 **Objectives and Plan of Work** 46-55

3.1 Rationale of study 46
3.2 Rationale of selection of FDCs 46
3.3 Objectives of study 47
3.4 Drug profiles 48
    Aceclofenac 48
    Paracetamol 48
    Marketed FDC tablets containing ACF and PCM 51
    Telmisartan 51
    Hydrochlorothiazide 53
    Marketed FDC tablets containing TEL and HCTZ 54
3.5 Plan of work 55
4 Experimental

4.1 Materials

4.2 Equipments

4.3 Physicochemical characterization and identification of drugs

4.4 Analytical method development and validation

4.4.1 Development and validation of UPLC-QTOF/MS method for simultaneous determination of aceclofenac, paracetamol and their degradation products

4.4.2 Development and validation of UPLC/Q-TOF-MS method for simultaneous determination of telmisartan, hydrochlorothiazide, and their degradation products

5 Results and Discussion

6 Summary and Conclusion

7 References

Appendix I: List of publications/proceedings arising out of Ph.D. research work